Latest Headlines

Latest Headlines

Sanofi science chief on Zika: It's time to disrupt traditional vaccine development

The World Health Organization has warned that the Zika R&D; frenzy may not culminate in a vaccine in time for the current outbreak, but Sanofi Chief Scientific Officer Gary Nabel won't take that for an answer. Nabel says it can be done, but it means turning the traditional vaccine development model on its head.

Amgen's PCSK9 patent win 'reasonably likely' to push Sanofi's Praluent off the market: Analyst

The analyst who warned that Sanofi and Regeneron could owe Amgen hefty royalties on its PCSK9 drug Praluent has come back with a prediction more dire: Chardan's Gbola Amusa says it's "reasonably likely" that the potential blockbuster would be removed from the market completely.

UPDATED: Sanofi denies that CEO considers moving HQ out of Paris

When Big Pharma companies get fed up with real estate costs in New York, they move to New Jersey. When you get tired of the high costs of Paris, they apparently move to Gentilly. At least that is what Sanofi's new CEO, Olivier Brandicourt, is considering as he looks at all avenues to cut costs for the beleaguered French company.

NIH-developed dengue vaccine protects all patients in challenge study

As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.

Amgen prevails in high-stakes PCSK9 patent fight with Sanofi, Regeneron

Amgen just won the first battle in a cholesterol-drug patent war that could be worth hundreds of millions in royalties per year. A Delaware jury decided Sanofi and Regeneron's PCSK9 drug Praluent did indeed step on Amgen's patents in the field.

Sarilumab's new Humira-beating data poses another threat to AbbVie's megablockbuster sales

AbbVie is watching competitors to top seller Humira come up the pipeline at several of its Big Pharma peers. And now, one of those competitors topped the rheumatoid arthritis behemoth in a late-stage trial.

Sanofi and Regeneron's would-be blockbuster tops Humira in arthritis

Sanofi and Regeneron, awaiting FDA approval for a potential blockbuster rheumatoid arthritis treatment, burnished the drug's profile with Phase III data showing it beat AbbVie's top-selling Humira head to head.

UPDATED: Sanofi Genzyme recalling Thyrogen from U.S., other countries

Sanofi's biotech unit Genzyme is recalling more than 36,000 vials of its thyroid cancer drug Thyrogen from the U.S., Puerto Rico and four other countries. Thyrogen is one of a several drugs that had been in short supply some years back after Genzyme ran into manufacturing issues.

Sanofi poaches Novartis exec Nathwani as new CMO

Sanofi announced that Novartis vet Ameet Nathwani has been named EVP and group chief medical officer, earning a seat on the executive committee.

Sanofi, Merck to split up their long-standing vaccines JV in Europe

Sanofi Pasteur MSD, the European vaccines joint venture between pharma giants Sanofi and Merck, has been around for 22 years. But now, the pair has decided that's long enough.